BioMarin | November 18, 2020
BioMarin Pharmaceutical Inc. and Deep Genomics declares that the organizations have gone into a preclinical collaboration that will use Deep Genomics' artificial intelligence drug discovery platform (The AI Workbench) to distinguish oligonucleotide drug applicants in four uncommon sickness signs with high neglected need. Deep Genomics will get an undisclosed forthright installment and is qualified to get improvement achievements as a piece of the coordinated effort. BioMarin will get an elite alternative to get Deep Genomics' privileges to each program for development and commercialization. The organizations didn't uncover financial terms.
In the cooperation, Deep Genomics will utilize its AI Workbench to recognize and approve target components and lead competitors, and BioMarin will propel them into preclinical and clinical development. The AI Workbench empowers quick investigation of novel targetable components and restorative up-and-comers. It joins deep learning, automation, progressed biomedical information and huge measures of in vitro and in vivo information to precisely recognize targetable sub-atomic systems and guide the revelation and advancement of oligonucleotide treatments.
TetraScience | September 03, 2021
TetraScience, the R&D Data Cloud company, announced today that Zymeworks Inc. has selected the Tetra Data Platform (TDP) to standardize and automate scientific data flow. As a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics, Zymeworks' R&D engine generates and analyzes large amounts of scientific data in its quest to revolutionize drug design.
"In order to take advantage of innovative data science applications including AI/ML, it's important to start with harmonizing R&D data in the cloud," stated Chad Garrett, TetraScience CRO, "We're excited to partner with Zymeworks on their data cloud initiative and help them deliver on their mission to enable patients to return home to their loved ones, disease free."
The initial Zymeworks deployment of Tetra Data Platform is in production and integrated with key systems and instruments supporting critical lab workflows. By automating and standardizing the flow of data across all sources and targets, the Tetra R&D Data Cloud will deliver faster and richer insights for Zymeworks' scientists. Additionally, Zymeworks will benefit from cloud-native architecture with greater uptime, security, redundancy, governance, and archival capabilities.
TetraScience is the R&D Data Cloud company with a mission to transform life sciences R&D, accelerate discovery, and improve and extend human life. The Tetra R&D Data Cloud provides life sciences companies with the flexibility, scalability, and data-centric capabilities to enable easy access to centralized, harmonized, and actionable scientific data and is actively deployed across enterprise pharma and biotech organizations. As an open platform, TetraScience has built the largest integration network of lab instruments, informatics applications, CRO/CDMOs, analytics, and data science partners, creating seamless interoperability and an innovation feedback loop that will drive the future of life sciences R&D.
Ligand Pharmaceuticals | July 29, 2021
Landing AI announced today that it has entered into a software licensing deal with Ligand Pharmaceuticals Incorporated to integrate LandingLens into Ligand's OmniAb and xPloration antibody discovery platforms. LandingLens is a software platform that offers an end-to-end process for developing, experimenting and delivering AI-powered visual inspection solutions.
The new AI-powered tools enhance Ligand's high-throughput single B cell screening accuracy and throughput in a wide range of complex biological assays, possibly increasing the output of antibodies with desired characteristics in less time.
"Landing AI, led by world-renowned AI pioneer Andrew Ng, is a proven and trusted partner in enabling their clients to achieve the business value of computer vision," says Bob Chen, Ph.D., Ligand Pharmaceuticals' Director, Systems Engineering. "We selected Landing AI because of its unique data-centric approach, which puts collecting high-quality data at the core of AI development. Notably, the LandingLens software platform includes plenty of data preparation tools and features that enable us to create reliable and consistent datasets that we can iterate on over time to improve our existing AI systems continuously."
"Deep learning and AI have emerged as strong technologies for enabling a wide range of vision-based applications. We are happy to be working with Ligand Pharmaceuticals and are dedicated to providing the best tools to assist our customers in unlocking the promise of AI, "said John Reuter, Landing AI's Vice President of Sales.
About Ligand Pharmaceuticals
Ligand is a revenue-generating biopharmaceutical company that focuses on creating or acquiring technologies that aid pharmaceutical companies in discovering new medicines. Ligand's business strategy adds value to stockholders by offering a diverse portfolio of biotech and pharmaceutical product revenue streams backed by an efficient and low corporate cost structure. Ligand's goal is to provide investors with the chance to participate in the biotech industry's promise through a profitable, diversified, and lower-risk business than a typical biotech firm. Ligand's business strategy is built on what the company specializes in drug discovery, early-stage drug development, product reformulation, and partnering. In addition, Ligand collaborates with other pharmaceutical firms to capitalize on their capabilities (late-stage development, regulatory management, and commercialization) to generate revenue.
About AI Landing
Using enablement tools, Landing AI enables clients to realize the business and operational benefits of computer vision. LandingLens, the company's main product, is an enterprise MLOps system that enables end-to-end processes for developing, iterating, and deploying AI-powered visual inspection solutions. As data quality is important to the achievement of production AI systems, LandingLens includes plenty of specially designed data preparation tools and processes to assist users in achieving optimum data accuracy and consistency. Dr. Andrew Ng, the co-founder of Coursera, former chief scientist of Baidu, and founding lead of Google Brain, founded Landing AI, guided by a data-centric AI approach, and is uniquely positioned to help companies successfully move their AI projects from proof-of-concept to full-scale production.